Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 401 - 450 out of 9,926

Document Document Title
WO/2009/124962A2
The invention relates to compounds of formula (I) wherein R1, R2, R4, Ra, Rb, Rc, Re, A*, W1, W2 and W3 are as defined in claim 1, for the treatment of CXCR3 related diseases.  
WO/2009/125606A1
Provided is a compound represented by formula (I) having a PAI-1 inhibiting action. [In formula (I), R1 represents an optionally substituted C6-10 aryl group etc., T represents a single bond etc., m is 0 or 1, when m is 0 G represents -N...  
WO/2009/124962A3
The invention relates to compounds of formula (I) wherein R1, R2, R4, Ra, Rb, Rc, Re, A*, W1, W2 and W3 are as defined in claim 1, for the treatment of CXCR3 related diseases.  
WO/2009/124022A1
The invention provides amino- and amido-aminotetralin compounds of formula (I) wherein R1, R2, R3, R4, R5, R6, R7, and n are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are antagonists at the mu opio...  
WO/2009/118292A1
The present invention provides a compound of formula (I):said compound is inhibitor of MMP-2, and/or MMP-8, and/or MMP-9, and/or MMP-12 and/or MMP-13, and thus can be employed for the treatment of a disorder or disease characterized by a...  
WO/2009/118168A1
The invention relates to compounds which have an affinity to the ยต-opioid receptor and ORL1 receptor, to processes for preparation thereof, to medicaments comprising these compounds and to the use of these compounds for producing medica...  
WO/2009/119858A1
Disclosed is a novel benzene compound which has an excellent immunosuppressing activity, an excellent rejection-inhibiting effect and others, and is reduced in adverse side effects including bradycardia. Specifically disclosed is a compo...  
WO/2009/115257A1
The invention relates to substituted sulfonamide derivatives, processes for the preparation thereof, medicament containing these compounds and the use of substituted sulfonamide derivatives for the preparation of medicaments.  
WO/2009/113704A3
The present invention provides an amphiphilic fluorine-containing compound having a structure represented by the following general formula (1) including a hydrophilic ligand Rl, a fluorine probe Rf, and linkers L1 and L2. In the formula,...  
WO/2009/111278A3
Compounds of Formula (I) are useful for inhibition of Raf kinases. Methods of using compounds of Formula (I) and stereoisomers, tautomers, prodrugs and pharmaceutically acceptable salts thereof, for in vitro, in situ, and in vivo diagnos...  
WO/2009/111280A1
Compounds of Formula (I) are useful for inhibition of Raf kinases. Methods of using compounds of Formula I and stereoisomers and pharmaceutically acceptable salts thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treat...  
WO/2009/111279A1
Compounds of Formula I are useful for inhibition of Raf kinases. Methods of using compounds of Formula I and stereoisomers, tautomers, prodrugs and pharmaceutically acceptable salts thereof, for in vitro, in situ, and in vivo diagnosis, ...  
WO/2009/111277A9
Compounds of Formula I are useful for inhibition of Raf kinases. Methods of using compounds of Formula I and stereoisomers and pharmaceutically acceptable salts thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatme...  
WO/2009/111277A1
Compounds of Formula I are useful for inhibition of Raf kinases. Methods of using compounds of Formula I and stereoisomers and pharmaceutically acceptable salts thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatme...  
WO/2009/106361A3
The present invention provides novel compounds that inhibit cell proliferation and uses of these compounds for treating, ameliorating or preventing diseases, conditions or disorders benefiting from the inhibition hyperproliferation.  
WO/2009/106361A2
The present invention provides novel compounds that inhibit cell proliferation and uses of these compounds for treating, ameliorating or preventing diseases, conditions or disorders benefiting from the inhibition hyperproliferation.  
WO/2009/103778A1
A compound of formula (1) as well as pharmaceutically acceptable salts thereof, and a pharmaceutical composition comprising the compound. The compound is useful for the treatment of disorder selected from pain, fever, inflammation and ca...  
WO/2009/105751A1
The present disclosure relates to acylsulfonamides and processes for their preparation. The processes involve a target-guided synthesis approach, whereby a thioacid and a sulfonyl azide are reacted in the presence of a biological target ...  
WO/2009/101201A2
The object of the present invention is mixtures of ionic and/or like hydrides and ionic liquids and use of such mixtures.  
WO/2009/101201A3
The object of the present invention is mixtures of ionic and/or like hydrides and ionic liquids and use of such mixtures.  
WO/2009/100095A1
Compounds according to the formula below are disclosed herein: Therapeutic methods for the treatment of pain, compositions, and medicaments related thereto are also disclosed.  
WO/2009/096526A1
Provided is a compound having a CRTH2 antagonism and being useful as a preventive and/or remedy for inflammatory diseases (for example, asthma, allergic rhinitis, allergic dermatitis, conjunctivitis, urticaria, eosinophilic bronchitis, f...  
WO/2009/096701A2
This present disclosure relates to novel compounds, isomer thereof or pharmaceutically acceptable salts thereof as vanilloid receptor (Vanilloid Receptor 1; VR1; TRPV1) antagonist; and a pharmaceutical composition containing the same. Th...  
WO/2009/096701A3
This present disclosure relates to novel compounds, isomer thereof or pharmaceutically acceptable salts thereof as vanilloid receptor (Vanilloid Receptor 1; VR1; TRPV1) antagonist; and a pharmaceutical composition containing the same. Th...  
WO/2009/096198A1
Disclosed is a novel biaryl derivative useful as an anti-cancer drug. A biaryl derivative represented by formula (I), or a pharmacologically acceptable salt thereof. [In formula (I), X represents an amino group substituted, for example, ...  
WO/2009/092590A3
A compound of the formula (I) where, for example, W, X and Y are each CH; R1 and R6, independently of each other, are for example, selected from the group consisting of H, C1-C6-alkyl, C2-C6-alkenyl, C2-C6-alkynyl, C1-C6-alkoxy, C3-C8-cy...  
WO/2009/092713A1
This invention relates to novel N-(2-methyl-phenyl-cyclopentyl)sulphonamide derivatives of formula (I) and salts thereof: wherein R1, R2, R3, R4, R5, R6, R7, R8, p, R9 and R10 are as defined in the description. The invention also relates...  
WO/2009/092712A1
This invention relates to by novel N-(phenyl-1, 3-cyclopentyl)sulphonamide derivatives formula (I) and salts thereof: wherein R1 to R9 and p are as defined in the description. The invention also relates to the use of the derivatives in t...  
WO/2009/087085A2
A compound of the formula (I) where W is N, NO, or C-R3; X is N, NO or C-R4; Y is N, NO, or C-R5; A is, for example, NR1R6; R1 and R6, independently of each other, are selected, for example, from the group consisting of H and C1-C6-alkyl...  
WO/2009/089192A1
The present invention provides novel phenoxyacetic acids useful for the prevention and treatment of inflammatory disorders, including those affecting the respiratory system and skin. The compounds are of the general formula (I):  
WO/2009/087085A3
A compound of the formula (I) where W is N, NO, or C-R3; X is N, NO or C-R4; Y is N, NO, or C-R5; A is, for example, NR1R6; R1 and R6, independently of each other, are selected, for example, from the group consisting of H and C1-C6-alkyl...  
WO/2009/088549A3
The present invention relates to compounds and methods for the treatment of bacterial infections. Because their mechanism of action does not involve killing of bacteria or inhibiting their growth, the potential for these compounds to ind...  
WO/2009/085177A1
Compounds, pharmaceutical compositions and methods are provided that are useful in the treatment of inflammatory and immune-related diseases and conditions. In particular, the invention provides compounds which modulate the function and/...  
WO/2009/080722A2
The invention provides novel compounds of formula (I), wherein: R1 is a radical derived from one of the known ring systems; R2 is a phenyl radical optionally substituted; Xn represents a birradical selected from the group consisting of: ...  
WO/2009/081956A1
Disclosed is a method for producing a conjugated aromatic compound, which is characterized in that an aromatic compound (A) having one or two leaving groups bonded to an aromatic ring is reacted with another aromatic compound (A) having ...  
WO/2009/082347A1
The invention provides compounds of formula (I) wherein R1,R3,L1,L2,G1,G2, A and m are as defined in the specification and optical isomers, racemates and tautomers thereof, and pharmaceutically acceptable salts thereof; together with pro...  
WO/2009/080637A1
Compounds of formula (I) and salts thereof are provided: wherein n is 0, 1, 2 or 3; R1 is selected from phenyl and pyridyl, each of which is optionally substituted by one or two groups independently selected from C1-4alkyl and halogen; a...  
WO/2009/080722A3
The invention provides novel compounds of formula (I), wherein: R1 is a radical derived from one of the known ring systems; R2 is a phenyl radical optionally substituted; Xn represents a birradical selected from the group consisting of: ...  
WO/2009/079375A1
Novel histone deacetylase inhibitors, including novel fluorescent histone deacetylase inhibitors, are described. Methods for making and using the same, e.g., to treat cancer, are provided.  
WO/2009/073427A1
The invention provides novel aryl and aliphatic esters of fluorinated alkanesulfonic acids. The invention also provides novel fluorinated alkanesulfonamides and a process to make the same. The invention also provides a process for the ar...  
WO/2009/071947A3
Compounds of formula (I) and pharmacologically acceptable salts wherein: Ar1 and Ar2 = aryl or heteroaryl; are excellent selective modulators of potassium ion flux.through KCNQ2, KCNQ3 and/or KCNQ2/3 channels, making them of use in treat...  
WO/2009/071947A2
Compounds of formula (I) and pharmacologically acceptable salts wherein: Ar1 and Ar2 = aryl or heteroaryl; are excellent selective modulators of potassium ion flux.through KCNQ2, KCNQ3 and/or KCNQ2/3 channels, making them of use in treat...  
WO/2009/066035A3
Combination of an anti-atherothrombotic and an angiotensin-converting enzyme inhibitor (ACEI), and also pharmaceutical compositions containing same. Medicaments  
WO/2009/067597A1
Compounds of the formula: (I) are disclosed. The compounds act as phosphodiesterase-4 modulators, and useful for treating stroke, myocardial infarct, and cardiovascular inflammatory conditions. Other embodiments are also disclosed.  
WO/2009/066035A2
Combination of an anti-atherothrombotic and an angiotensin-converting enzyme inhibitor (ACEI), and also pharmaceutical compositions containing same. Medicaments  
WO/2009/064449A1
Compounds are disclosed that have a formula represented by the following: The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of a variety of conditions in mammals including huma...  
WO/2009/064250A1
The invention provides compounds of formula wherein R1, R2 , R3, A and m are as defined in the specification and optical isomers, racemates and tautomers thereof, and pharmaceutically acceptable salts thereof; together with processes for...  
WO/2009/064251A1
The invention provides compounds of formula wherein R1, R3, L1, L2, G1, G2, A and m are as defined in the specification and optical isomers, racemates and tautomers thereof, and pharmaceutically acceptable salts thereof; together with pr...  
WO/2009/061652A8
Compounds of formula (I) are disclosed. Compounds according to the invention bind to and are agonists of the CB2 receptor, and are useful for treating inflammation. Those compounds which are agonists are additionally useful for treating ...  
WO/2009/061652A1
Compounds of formula (I) are disclosed. Compounds according to the invention bind to and are agonists of the CB2 receptor, and are useful for treating inflammation. Those compounds which are agonists are additionally useful for treating ...  

Matches 401 - 450 out of 9,926